Synthetic Biology Market to HIt $5.6304 Billion by 2018 – New Research Report by MarketsandMakets

(PRWEB) December 13, 2014

The Global Synthetic Biology Market (2013-2018), analyses and studies the major market drivers, threats, opportunities, and challenges.

The global synthetic biology market is dominated by three major players, namely, Thermo Fisher Scientific, Inc. (U.S.), DuPont (U.S.), and Royal DSM N.V. (Netherlands). These players jointly accounted for approximately ~65% of the total synthetic biology market.

Full Copy for This Report @ http://www.marketsandmarkets.com/Market-Reports/synthetic-biology-market-889.html

Thermo Fisher Scientific, Inc. (U.S.) accounted for the largest share of the synthetic biology market. The company offers a wide product portfolio which includes GeneArt CRISPR products, Gateway Cloning Technology, and GeneArt Seamless Cloning and Assembly products, and synthetic biology services such as GeneArt Plasmid, Protein Expression, and Pathway Engineering and Vector Construction. The company has its manufacturing operations in 150 countries, across North America, Europe, Asia, and Latin America, and aims to expand its customer base by expanding its research, development, training, manufacturing, and commercial capabilities in the high-growth markets of the Asia-Pacific region. Additionally, it emphasizes on sales and marketing activities in order to grow its business. It markets and sells its products and services through a direct sales force, third-party distributors, customer service professionals, and electronic commerce. As of 2013, the company had approximately 14,300 sales and service personnel, which also included over 2,000 highly trained technical specialists who cater to the technical needs of the firms customers. Moreover, to maintain its leadership position in the synthetic biology market, the company resorts to growth strategies such as agreements and acquisitions.

Speak to Analyst for More Inquiry @ http://www.marketsandmarkets.com/speaktoanalyst.asp?id=889

The synthetic biology market is rapidly evolving, with various technological advancements that have resulted in a paradigm shift within the market. This has resulted in advanced production of synthetic genes and chassis to develop synthetic organisms from scratch.

Royal DSM N.V. (Netherlands) is the second-leading player in the synthetic biology market. The companys product offerings in the field of synthetic biology include active pharmaceutical ingredients (APIs) such as semi-synthetic cephalosporins, semi-synthetic penicillins, and nystatin. In addition, it develops material-based solutions such as drug delivery platforms and biomedical materials for medical device and biopharmaceutical industries. It also creates solutions for bioconversion of feedstocks to produce cellulosic biofuels. The company focuses on research and development and sells its products through a direct sales force in the U.S., Latin America, Europe, South Africa, Australia, China, Indonesia, and Japan. In the other markets, the firm provides its products through distributors.

About MarketsandMarkets

MarketsandMarkets is worlds No. 2 firm in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors.

See the article here:
Synthetic Biology Market to HIt $5.6304 Billion by 2018 - New Research Report by MarketsandMakets